Angiogenesis in chronic viral hepatitis

Gastroenterologia Polska

Volumn 16, Issue 4, 2009, Pages 304-309

  Kukla, Michał ^a   Gabriel, Andrzej ^a   Waluga, Marek ^a   Bułdak, Rafał ^a   Mazur, Włodzimierz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiogenesis; Fibrosis; Hepatocyte growth factor; Inflammation; Liver; Vascular endothelial growth factor; Viral hepatitis

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; EPHRIN; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOCYTE ENHANCER FACTOR 2; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 6; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CHRONIC HEPATITIS; DISEASE COURSE; EXTRACELLULAR MATRIX; HEPATITIS VIRUS; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; VASCULAR SURGERY; VIRUS HEPATITIS;

EID: 70449584871     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Medina J., Arroyo A.G., Sanchez-Madrid F., Moreno-Otero R.: Angiogenesis in Chronic Inflammatory Liver Disease. Hepatol., 2004, 39, 1185-1195.
2. Chaparro M., Sanz-Cameno P., Trapero-Marugan M., Garcia-Buey L., Moreno-Otero R.: Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann. Hepatol., 2007, 6, 208-213.
3. Carmeliet P.: Angiogenesis in health and disease. Nat. Med., 2003, 9, 653-660.
4. Amarapurkar A.D., Amarapurkar D.N., Vibhav., Patel N.D.: Angiogenesis in chronic liver disease. Ann. Hepatol., 2007, 6, 170-173.
5. Folkman J.: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
6. Pugh C.W., Rateliffe P.J.: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 2003, 9, 677-684.
7. Shimizu I.: Antifibrogenic Therapies in chronic HCV Infection. Curr. Drug Targets Infect. Disord., 2001,1, 227-240.
8. Novo E., Cannito S., Zamara E., di Bonzo L.V., Caligiuri A., Cravanzola C., Compagnone A., Colombatto S., Marra F., Pinzani M., Parola M.: Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am. J. Pathol., 2007, 170.
9. McCuskey R.S., Reilly F.: Hepatic microvasculature: dynamic structure and its regulation. Semin. Liver Dis., 1993, 13, 1-12.
10. Camenisch G., Pisabarro M., Sherman D., Kowalski J., Nagel M., Hass P., Xie M.H., Gurney A., Bodary S., Liang X.H., Clark K., Beresini M., Ferrara N., Gerber H.P.: ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J. Biol. Chem., 2002, 227, 17281-17290.
11. Murohara T., Asahara T., Silver M., Bauters C., Masura H., Kalka C., Kearney M., Chen D., Symes J.F., Fishman M.C., Huang P.L., Isner J.M.: Nitric oxide synthase modulates angiogenesis In response to tissue ischemia. J. Clin. Invest., 1998, 101, 2567-2578.
12. Hiraoka N., Allen E., Apel I., Gyetko M., Weiss S.: Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell., 1998, 95, 365-377.
13. Jackson C.: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens., 2002, 11, 295-299.
14. Hynes R.O.: A reevaluation of integrins as mediators of angiogenesis. Nat. Med., 2002, 8, 918-921.
15. Galvez B.G., Matias-Roman S., Albar J., Sanchez-Madrid F., Arroyo A.: Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem., 2001, 276, 37291-37500.
16. Luttun A., Dewerchin M., Collen D., Carmeliet P.: The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep., 2000, 2, 497-1416
17. Ferrara N., Gerber H., LeCouter J.: The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676.
18. Yancopoulos G.D., Davis S., Gale N., Rudge J., Wiegand S., Holash J.: Vascular-specific growth factors and blood vessel formation. Nature., 2000, 407, 242-248.
19. Jain R.K.: Molecular regulation of vessel maturation. Nat. Med., 2003, 9, 685-693.
20. Kalluri R.: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer., 2003, 3, 422-433.
21. Hellstrom M., Gerhardr H., Kalen M., Li X., Eriksson U., Wolburg H., Betsholtz C.: Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol., 2001, 153, 543-553.
22. Thurston G., Rudge J., Ioffe E., Zhou H., Ross L., Croll S., Glazer N., Holash J., McDonald D.M., Yancopoulos G.D.: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med., 2000, 6, 460-463.
23. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., Dijke Pt.: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J., 2002, 21, 1743-1753.
24. Garcia-Monzon C., Sanchez-Madrid F., Garcia-Buey L., Garcia-Arroyo A., Garcia-Sanchez A., Moreno-Otero R.: Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastoenterol., 1995, 108, 231-241.
25. Pinzani M., Marra F.: Cytokine receptors and signaling in hepatic stellate cells. Semin. Liver Dis., 2001, 21, 397-416.
26. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J.: Angiogenesis In liver disease. J. Hepatol., 2009, 50, 604-620.
27. Novo E, Parola M.: Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair., 2008, 13, 5.
28. Aleffi S., Petrai I, Bertolani C., Parola M., Colombatto S., Novo E., Vizzutti F., Anania F.A., Milani S., Rombouts K., Laffi G., Pinzani M., Marra F.: Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology., 2005, 42, 1339-1348.
29. Mazzanti R., Messerini L., Monsacchi L., Buzzelli G., Zignego A., Foschi M.: CVH induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatol., 1997, 25, 229-234.
30. Messerini L., Novelli L., Comin C.E.: Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J. Clin. Pathol., 2004, 57, 867-871.
31. Ohmori S., Shiraki K., Sugimoto K., Sakai T., Fujikawa K., Wagayama H., Takase K., Nakano T.: High expression of CD34-positive sinusoidal endothelial cells is risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum. Pathol., 2001, 32, 1363-1370.
32. Majano P.L., Garcia-Monzon C., Lopez-Cabrera M., Lara-Pezzi E., Fernandez-Ruiz E., Garcia-Iglesis C., Borque MJ., Moreno-Otero R.: Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J. Clin. Invest., 1998, 101, 1343-1352.
33. Majano P., Lara-Pezzi E., Lopez-Cabrera M., Apolinario A., Moreno-Otero R., Garcia-Monzon C.: Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor kappaB-binding site: evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatol., 2001, 34, 1218-1224.
34. Shimoda K., Mori M., Shibuta K., Banner B., Barnard G.: Vascular endothelial growth factor/vascular permeability factor mRNA expression in patient with chronic hepatitis C and hepatocellular carcinoma. Inr. J. Oncol., 1999, 14, 353-359.
35. Okano J.I., Shiota G., Kawasaki H.: Expression of hepatocyte growth factor (HGF) an HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver., 1999, 19, 151-159.
36. Medina J., Caveda L., Sanz-Cameno P., Arroyo A., Martin-Vilchez S., Majano P., García-Buey L., Sánchez-Madrid F., Moreno-Otero R.: Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J. Hepatol., 2003, 35, 660-667.
37. Zwirska-Korczala K., Kukla M., Ziolkowski A., Janczewska-Kazek E., Berdowska A., Sitkiewicz A., Dziambor A., Wiczkowski A., Gabriel A.: Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp. Clin. Hep., 2005 1, 0R60-65.
38. Kukla M., Warakomska I., Gabriel A., Żwirska-Korczala K., Rybus-Kalinowska B., Berdowska A., Kalinowski M., Chwist A., Waluga M., Kuka M., Kȩpa L.: Serum levels of sICAM-1, TNFα, sTNF-R1, and sTNF-R2 in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Exp. Clin. Hep., 2008, 4, OR12-20.
39. Salcedo X., Medina J., Sanz-Cameno P., Garcia-Buey L., Martin-Vilchez S., Borque M.J., López-Cabrera M., Moreno-Otero R.: The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatol., 2005, 42, 696-701.
40. Lara-Pezzi E., Roche S., Andrisani O., Sanchez-Madrid F., Lopez-Cabrera M.: The hepatitis B virus HBx protein induces adherent junction disruption In a src-dependent manner. Oncogene., 2001, 20, 3323-3331.
41. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., Cheresh D.A.: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell., 1999, 4, 915-924.
42. Sanz-Cameno P., Martin-Vilchez S., Lara-Pezzi E., Borque M.J., Salmeron J., Munoz de Rueda P., Solís J.A., López-Cabrera M., Moreno-Otero R.: Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am. J. Pathol., 2006, 169, 1215-1222.
43. Lara-Pezzi E., Gomez-Gaviro M.V., Galvez B.G., Mira E., Iniguez M.A., Fresno M., Martínez-A.C., Arroyo AG., López-Cabrera M.: The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J. Clin. Invest., 2002, 110, 1831-1838.
44. Garcia-Monzon C., Garcia-Buey L., Majano P., Moreno-Otero R.: Integrins: structure, biological functions and relevance in viral chronic hepatitis. Eur. J. Clin. Invest., 1995, 25, 71-78.
45. Kiosses W.B., Shattil S., Pampori N., Schwartz M.: Rac recruits high-affinity integrin avb3 to lamellipodia in endothelial cell migration. Nat. Cell. Biol., 2001, 3, 316-320.
46. Lai W.K., Adams D.H.: Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J. Hepatol., 2005, 45, 7-11.
47. Girard J.P., Springer T.A.: High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today., 1995, 16, 449-457.
48. Mazzanti R., Messerini L., Monsacchi L., Buzzelli G., Zignego A.L., Foschi M., Monti M., Laffi G., Morbidelli L., Fantappié O., Bartoloni Saint Omer F., Ziche M.: CVH induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology., 1997, 25, 229-234.
49. Van Belle E., Witzenbichler B., Chen D., Silver M., Chang L., Isner J.: Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation., 1998, 97, 381-390.
50. Ikura Y., Morimoto H., Ogami M., Jomura H., Ikeoka N., Sakurai M.: Expression of platelet-derived growth factor and its receptor In livers of patients with chronic liver disease. J. Gastroenterol., 1997, 32, 496-501.
51. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., Caligiuri A., Pellegrini G., Ngo D.V., Romanelli R.G., Gentilini P.: Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol., 1996, 148, 785-800.
52. Lindahl P., Hellstrom M., Kalen M., Betsholtz C.: Endothelial perivascular cell signaling in vascular development: lessons from knockout mice. Curr. Opin. Lipidol., 1998, 9, 407-411.
53. Janczewska-Kazek E., Marek B., Kajdaniuk D., Ziółkowski A., Kukla M.: Correlation between TGF-beta1, VEGF, HGF, EGF, TGF-alpha and FGF serum levels, necroinflammatory activity and fibrosis in chronic hepatitis C. Exp. Clin. Hep., 2005, 1, OR24-28.
54. Salcedo X., Medina J., Sanz-Cameno P., Garcia-Buey L., Martin-Vilchez S., Moreno-Otero R.: Review article: angiogenesis soluble factors as liver disease markers. Aliment. Pharmacol. Ther., 2005, 22, 23-30.
55. Kukla M., Zwirska-Korczala K., Gabriel A., Janczewska-Kazek E., Berdowska A., Wiczkowski A., Rybus-Kalinowska B., Kalinowski M., Ziółkowski M., Woźniak-Grygiel E., Waługa M., Nowak B.: sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Ther. Adv. Gastroenterol., 2009, 2, 79-90.
56. Zwirska-Korczala K., Kukla M., Ziolkowski A., Janczewska-Kazek E., Berdowska A., Rybus-Kalinowska, Korzonek-Szlacheta I., Wiczkowski A., Gabriel A.: The usefulness of sPECAM-1 (sCD 31) serum concentration measurement in chronic hepatitis C. Exp. Clin. Hep., 2006, 2, OR55-59.
57. Bertolini C., Marra F.: The role of adipokines in liver fibrosis. Pathophysiology., 2008, 15, 91-101.
58. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., Madge LA., Schechner JS., Schwabb MB., Polverini PJ., Flores-Riveros JR.: Biological action of leptin as an angiogenic factor. Science., 1998, 281, 1683-1686.
59. Piche T., Vandenbos F., Abakar-Mahamat G., Vanbiervliet G., Barjoan E.M., Calle G., Giudicelli J., Ferrua B., Laffont C., Benzaken S., Tran A.: The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J. Viral. Hepatol., 2004, 11, 91-96.
60. Shimizu H., Kakizak S., Tsuchiya T., Nagamine T., Takagi H., Takayama H., Kobayashi I., Mori M.: An increase of circulating leptin in patients with liver cirrhosis. Int. J. Obesity., 1998, 22, 1234-1238.